brainplotting.com

What It Is

BrainPlotting is a specialized service provider focused on human brain PK prediction, with a background related to blood-brain barrier (BBB) models and human brain pharmacokinetics. Based on the website content, it is not a traditional SaaS or enterprise software product, but is closer to an R&D service or CRO-style capability provider for pharmaceutical and biotechnology companies. Its proposition is to use fresh human brain tissue and primary cell cultures to make preclinical predictions closer to the real human environment.

Core Capabilities

Its core offering revolves around three areas: first, BBB, or blood-brain barrier-related models, used to understand the limitations of molecules entering the brain; second, PBPK modeling, which uses physiological and drug-specific parameters to predict drug exposure; and third, Human Tissue, emphasizing the individuality and human-specific characteristics of human brain tissue in terms of composition, proteins, lipids, and other aspects. Its services include predicting molecular concentrations in brain parenchyma, as well as supporting in vivo and preclinical-stage R&D decisions through pharmacology and toxicology tools.

Pricing and Productization

The website does not disclose packages, unit pricing, free trials, payment methods, or standard service bundles. Based on the description, it is more likely to use project-based, consulting-based, or customized experimental service pricing rather than an online subscription SaaS model. There is also no mention of common enterprise software capabilities such as cloud deployment, self-hosting, APIs, developer documentation, third-party integrations, or team permissions.

Pros and Cons

Its strengths lie in its clear professional focus, with differentiation around human brain PK, BBB, and CNS/peripheral target molecule development. It also claims to have a network of key opinion leaders in French neurosurgery and patient associations, enabling access to healthy and pathological human brain tissue. The limitations are also obvious: publicly available information is limited, and there is a lack of validation data, case studies, pricing, delivery workflows, and compliance explanations. Many pages in the crawled content are 404s, which affects credibility and the completeness of evaluation.

Who It’s For and Access from China

It is suitable for pharmaceutical companies, biotechnology firms, and neurological disease R&D teams that need to evaluate brain exposure, BBB permeability, and pharmacology/toxicology risks at the preclinical stage. Access from China cannot be determined from the text and is marked as unknown. If collaboration is needed, it is recommended to contact the company directly to confirm sample sources, ethics compliance, data delivery methods, and the feasibility of cross-border collaboration.